Drug discovery and developer Larkspur Biosciences has launched out of stealth with USD 35.5 million in seed and Series A funding. The round was led by the Polaris Innovation Fund, 3E Bioventures Capital, and Takeda Ventures, Inc., and included other investors Creacion Ventures, Med-Fine Capital, and Cornell University.
The funds will be used for preclinical work on its lead program and will also support research on its secondary program.
Larkspur Biosciences is a preclinical biotechnology startup focused on developing precision immunotherapies, beginning with colorectal cancer (CRC) characterized by specific genetic and immunological features. Larkspur's approach is based on cancer cell biology and immunology, leveraging patient genetics and immune phenotypes through its proprietary platform, LarkX. The company has three programs in its pipeline focusing on CRC, with opportunities to expand to multiple cancers.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.